198 related articles for article (PubMed ID: 34528551)
1. Intensity modulated radiotherapy in anal canal squamous cell carcinoma: Implementation and outcomes.
Das A; Arunsingh M; Bhattacharyya T; Prasath SS; Balakrishnan A; Mallick I
J Cancer Res Ther; 2021; 17(4):975-981. PubMed ID: 34528551
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
4. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
5. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of definitive radiation with volumetric modulated arc therapy and concurrent chemotherapy for squamous cell carcinoma of the anus in a regional Australian cancer centre.
Hsieh MT; Shakespeare TP; Winkley L; Goonetilleke D; Yap SZL; Tahir ARM
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):325-332. PubMed ID: 38450897
[TBL] [Abstract][Full Text] [Related]
7. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
8. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
9. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
[TBL] [Abstract][Full Text] [Related]
11. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
12. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
[TBL] [Abstract][Full Text] [Related]
13. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
Singh K; Sathyamurthy A; Ramireddy JK; Ram TS
J Gastrointest Cancer; 2022 Mar; 53(1):161-169. PubMed ID: 33400211
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
Elson JK; Kachnic LA; Kharofa JR
Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy.
Foster CC; Lee AY; Furtado LV; Hart J; Alpert L; Xiao SY; Hyman NH; Sharma MR; Liauw SL
PLoS One; 2018; 13(3):e0194234. PubMed ID: 29522569
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
[TBL] [Abstract][Full Text] [Related]
19. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
Belgioia L; Vagge S; Agnese D; Garelli S; Murialdo R; Fornarini G; Chiara S; Gallo F; Bacigalupo A; Corvò R
World J Gastroenterol; 2015 Oct; 21(37):10688-96. PubMed ID: 26457030
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
